Investment Rating - The report initiates coverage on Zai Lab with a "Buy" rating and a target price of RMB 166.16 [1][6] Core Insights - Zai Lab is a leading player in the TCE (T cell engager) field, with its flagship product ZG006 (DLL3/DLL3/CD3) expected to achieve a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion [2][19] - The company has four innovative drugs already approved for sale in China, providing a sustainable cash flow to support early-stage R&D pipelines [1][15] - Zai Lab has partnered with AbbVie to expand ZG006 into international markets, which is anticipated to accelerate clinical progress and enhance market penetration [2][19] Summary by Sections Investment Rating - The report assigns a "Buy" rating to Zai Lab with a target price of RMB 166.16 [1][6] Market Potential - ZG006 is projected to have a domestic peak sales of over RMB 4 billion and an overseas peak of nearly USD 6 billion, driven by the high unmet medical need in small cell lung cancer (SCLC) [2][19] - The report highlights the potential for ZG006 to achieve a significant market share in the first-line SCLC treatment, with expectations of a 30% peak market share due to AbbVie's commercialization capabilities [5][19] Product Pipeline - Zai Lab has a robust pipeline with multiple innovative drugs, including ZG005 (PD-1/TIGIT) and ZGGS34 (MUC17/CD3/CD28), which are in various stages of clinical trials [4][22] - The company has successfully commercialized four innovative drugs, including Donafenib, which generated approximately RMB 530 million in sales in 2024 [3][15] Financial Projections - The report forecasts Zai Lab's revenue to grow from RMB 843 million in 2025 to RMB 2.22 billion in 2027, with a projected net profit of RMB 5.46 million in 2025 [6][10] - The DCF valuation method estimates a target market capitalization of RMB 43.98 billion, corresponding to the target price of RMB 166.16 [6][10]

Group 1: Real Estate Sector - Recent performance of AH real estate stocks has outperformed market indices, with the Hong Kong real estate index rising by 7.3% and the A-share real estate index increasing by 5.5% from January 19 to 29 [2] - The valuation recovery of real estate stocks is driven by low valuations and multiple factors, including improved liquidity in Hong Kong and expectations of marginal improvement in the real estate fundamentals [2] - The period until March is seen as a window for policy and market recovery, which may support continued valuation recovery for real estate stocks [2] Group 2: Consumer Services - The State Council has issued a plan to accelerate the cultivation of new growth points in service consumption, focusing on six key areas and three potential sectors [3] - The plan aims to enhance service consumption, which is expected to drive a shift from online to offline spending, benefiting related industries such as dining, tourism, and retail [3] - The long-term outlook for service consumption in China is positive, with significant growth potential as consumer demand continues to evolve [3] Group 3: Fixed Income and Convertible Bonds - The convertible bond market has seen a resurgence, with a 7.69% increase in the convertible bond index, outperforming major stock indices [4] - The market is benefiting from seasonal stock market trends and inflows into "fixed income plus" products, indicating a strong trading environment for convertible bonds [4] - The focus is shifting towards trading attributes as the investment value in convertible bonds diminishes [4] Group 4: Utilities Sector - The demand for natural gas in China's manufacturing sector is expected to grow moderately, with a 2% annual growth rate from 2026 to 2028, but with significant structural differentiation [6] - Emerging manufacturing sectors are projected to see the highest demand growth, while traditional high-energy-consuming industries are expected to decline [6] - The transformation of the city gas industry towards comprehensive energy services presents core opportunities for companies capable of adapting to these changes [6] Group 5: Pharmaceutical Sector - Zai Lab is recognized as a leading player in the T-cell engager (TCE) field, with its product ZG006 expected to achieve significant domestic and international sales [7] - The company has four innovative drugs already on the market, providing a sustainable cash flow to support ongoing research and development [7] - The target price for Zai Lab is set at 166.16 yuan, reflecting strong growth potential in the TCE market [7] Group 6: Electric Equipment and New Energy - TBEA is expected to benefit from a favorable market environment in 2026, with multiple business segments entering a growth phase [8] - The company is projected to see increased demand for its power transmission and transformation equipment due to global shortages [8] - The target price for TBEA is set at 33.31 yuan, indicating strong earnings potential in the coming years [8] Group 7: Social Media Sector - Meta's Q4 2025 revenue grew by 24% year-on-year to $59.9 billion, driven by significant improvements in advertising efficiency due to AI [9] - The company expects Q1 2026 revenue to reach between $53.5 billion and $56.5 billion, exceeding market expectations [9] - The introduction of new AI-driven products is anticipated to further enhance revenue growth in 2026 [9] Group 8: Education Sector - TAL Education reported a 27% year-on-year revenue increase in Q3 FY26, driven by strong growth in its K12 business [11] - The company has maintained a high operating profit margin, significantly exceeding market expectations [11] - The outlook for TAL Education remains positive, with continued growth anticipated in its educational services [11] Group 9: Agriculture Sector - Shennong Group is expected to face a decline in net profit for 2025 due to falling pig prices, but maintains a strong growth outlook due to cost advantages [10] - The company is positioned as a rare growth and financially stable entity within the current pig cycle [10] - The target price for Shennong Group remains favorable, reflecting its potential for recovery and growth [10]